Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Equity Average (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Equity Average for 4 consecutive years, with -$430.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average fell 95.31% to -$430.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$430.4 million, a 95.31% decrease, with the full-year FY2025 number at -$345.9 million, down 111.97% from a year prior.
  • Equity Average was -$430.4 million for Q4 2025 at Phathom Pharmaceuticals, down from -$414.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $15.5 million in Q2 2022 to a low of -$430.4 million in Q4 2025.
  • A 4-year average of -$164.1 million and a median of -$110.6 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 99.48% in 2023, then crashed 243218.5% in 2024.
  • Phathom Pharmaceuticals' Equity Average stood at -$50.6 million in 2022, then rose by 10.57% to -$45.3 million in 2023, then crashed by 386.78% to -$220.3 million in 2024, then tumbled by 95.31% to -$430.4 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Equity Average are -$430.4 million (Q4 2025), -$414.2 million (Q3 2025), and -$372.1 million (Q2 2025).